CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT07222215
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:35.311732+00:00
Published At: 2026-01-22T00:00:00+00:00
Record Updated At: 2026-01-22
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Estrogen-receptor-positive Breast Cancer", "Metastatic Breast Cancer", "Breast Cancer", "Hormone Receptor Positive Breast Cancer", "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast", "HER2- Breast Cancer", "ESR1 Gene Mutation", "ER Wildtype", "Breast Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-22"
protocolSection.identificationModule.nctId: "NCT07222215"
protocolSection.identificationModule.officialTitle: "A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.